Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser

Executive Summary

MedImmune will initiate a 60,000-patient, open-label safety study for FluMist by Sept. 30 as a Phase IV commitment following the June 17 approval of the intranasal flu vaccine
Advertisement

Related Content

FluMist Price Likely To Be Cut To $20-$25 Per Dose, MedImmune Says
MedImmune To Continue FluMist Development; Wyeth Remains Undecided
Gilead Leads Biotech Rebound In 2003: Product Stories Play Well
FluMist Picks Up Insurance Reimbursement, CDC Endorsement After Outbreak
Wyeth Offering FluMist Coupons; Prevnar Supply Issue “Resolved,” FDA Says
MedImmune Aims To Double Pharmacies Offering FluMist; WalMart Passes
FluMist Arriving Ahead Of Schedule; Could Aid Sales, MedImmune Says
FluMist Storage Concerns Discourage Coverage Recommendation From ACIP
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
Advertisement
UsernamePublicRestriction

Register

PS042005

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel